Can Novo, Lilly Take Credit for U.S. Obesity Rate Decline?
Trending Stocks This Week as Strong Jobs Report Underscore Resilience of U.S. Economy
iPhone Assembler Foxconn Posts Record Q3 Revenue
Apple Cleared in iPhone Security Patent Case: Report
Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages
10 Information Technology Stocks Whale Activity In Today's Session
AI Stocks Ripping, Barn Burner Jobs Report - Could Powell Be Wrong?
Evaluating Eli Lilly Against Peers In Pharmaceuticals Industry
Market Clubhouse Morning Memo - October 4th, 2024 (Trade Strategy For SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META And TSLA)
This Is What Whales Are Betting On Apple
Meta Enters Gen-AI Video Arena With Movie Gen, but Release Date Unknown
England's NHS Proposes Phased Rollout of Eli Lilly's Mounjaro, Considers Digital Services to Boost Access
Apple Set To Open 4 New Retail Stores In India As Tech Giant Looks To Build On Retail Success
US regulators said eli lilly and co's weight loss miracle drug is no longer in short supply, with 'substitute' manufacturer Hims & Hers plunging more than 10% during trading.
FDA stated that eli lilly and co's two exenatide-containing GLP-1 injection Zepbound and Mounjaro have been in short supply since 2022 due to increased demand, but the shortage issue is now resolved. Industry organizations say that FDA's determination equals to pharmacies stopping the allocation and distribution of generic versions of the two drugs.
Wells Fargo's 'Core' Stocks: GOOGL, HD, KO, and More
Cracking The Code: Understanding Analyst Reviews For Eli Lilly
Apple Analyst Ratings
Eli Lilly Analyst Ratings
BofA's Top 10 Growth Stocks for October
Hims & Hers Health Stock Is Tumbling Thursday: Here's Why